FRE Stock Chart & Stats
CHF39.86
CHF4.00(11.15%)
At close: 4:00 PM EDT
CHF39.86
CHF4.00(11.15%)
Day’s Range― - ―
52-Week RangeCHF31.73 - CHF53.06
Previous CloseN/A
Volume272.00
Average Volume (3M)0.00
Market Cap
CHF23.16B
Enterprise ValueCHF35.49K
Total Cash (Recent Filing)CHF2.06B
Total Debt (Recent Filing)CHF11.90B
Price to Earnings (P/E)16.7
Beta0.20
Next Earnings
Aug 05, 2026EPS Estimate
0.82Next Dividend Ex-DateN/A
Dividend Yield2.42%
Share Statistics
EPS (TTM)2.66
Shares Outstanding563,237,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF50.28Price Target Upside26.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)3.3
Revenue Forecast (FY)CHF22.09B
Bulls Say, Bears Say
Bulls Say
Recurring Dialysis & Integrated Care ModelFresenius’s core dialysis business provides recurring, payer-reimbursed treatment revenues and product sales, creating durable cash flows and high utilization visibility. The integrated model (care delivery plus product supply) supports cross-selling and stable patient-based demand over multi-year horizons.
Margin And Profitability RecoveryMargins and net income recovered materially from 2023 lows, with EBIT margin rising and net margin turning positive. Sustained margin improvement signals better operational control and pricing or mix gains, supporting durable earnings power if the company maintains cost discipline and service volumes.
Solid Free Cash Flow GenerationConsistent positive operating and free cash flow, including a strong TTM rebound, indicates the business can fund operations, capex and deleveraging from internal cash. Reasonable cash conversion of net income into FCF underpins financial flexibility and supports reinvestment or debt reduction over time.
Bears Say
Sizable Absolute Debt LoadAlthough debt-to-equity has fallen, the large absolute debt stock (~€11.9B) limits financial flexibility and increases sensitivity to interest costs or slower cash flow. In adverse conditions, sizable liabilities reduce cushion for strategic investments and heighten refinancing and credit risks over the medium term.
Choppy Multi-year Revenue TrajectoryRevenue has been volatile across years, including a sharp decline in 2023 and still-below-2021 levels, which raises questions about sustained demand growth and pricing stability. This uneven top-line undermines predictability of margins and cash flow, complicating medium-term planning and capital allocation.
Volatile Free Cash Flow And Modest Cash MarginsAlthough FCF is positive, it has shown large swings year-to-year and operating cash flow is modest versus revenue. This volatility reduces the reliability of internal funding for growth or deleveraging and increases reliance on careful working-capital and capex management to sustain long-term investments.
Fresenius SE & Co. KGaA News
FRE FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest stock price was CHF31.73 and its highest was CHF53.06 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Fresenius SE & Co. KGaA’s market cap is CHF23.16B.
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Aug 05, 2026 which is yesterday.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Currently, no data Available
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA pays a Annually dividend of CHF0.979 which represents an annual dividend yield of 2.42%. See more information on Fresenius SE & Co. KGaA dividends here
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is 0.82.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in CH:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co. KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF50.28 (26.13% Upside)
CHF50.28 (26.13% Upside)
Insider Transactions
Bought Shares
Worth CHF466.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.91%
12-Months-Change
Fundamentals
Return on Equity
2.42%
Trailing 12-Months
Asset Growth
-1.94%
Trailing 12-Months
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
FRE Stock 12 Month Forecast
Average Price Target
CHF50.28
▲(26.13% Upside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius Medical Care AG & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―








